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Abstract—The authentic standards GSK1482160 and its isomer, as well as the radiolabeling precursors desmethyl-GSK1482160 and 
Boc-protected desmethyl-GSK1482160 were synthesized from L-pyroglutamic acid, methyl L-pyroglutamate and 2-chloro-3-
(trifluoromethyl)benzylamine with overall chemical yield 27-28% in 3 steps, 58% in 4 steps, 76% in 1 step and 33% in 2 steps, 
respectively. [11C]GSK1482160 was prepared from either desmethyl-GSK1482160 or Boc-protected desmethyl-GSK1482160 with 
[11C]CH3OTf through N-[
11C]methylation and isolated by HPLC combined with SPE in 40-50% and 30-40% radiochemical yield,
respectively, based on [11C]CO2 and decay corrected to end of bombardment (EOB). The radiochemical purity was >99%, and the
specific activity at EOB was 370-1110 GBq/mol with a total synthesis time of ~40-minutes from EOB.   
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The purinergic receptor P2X ligand-gated ion chanel 
type 7 (P2X7 receptor) is an adenosine triphosphate 
(ATP)-gated ion-channel. It is found in the immune, 
peripheral, and central nervous systems; implicated in 
ATP-mediated cell death, regulation of receptor 
trafficking and inflammation; and associated with 
various cancer, neurological and cardiovascular 
disorders.
1-4
 Neuroinflammation is considered to play an
important role in a variety of neuropathologies, such as 
Alzheimer’s disease, Parkinson’s disease and traumatic 
brain injury.
5-7
 P2X7 receptor antagonists have been
developed as potential pharmaceuticals for the treatment 
of various diseases including neuroinflammation.
8-10
We are interested in biomedical imaging to detect and 
quantify neuroinflammation, with positron emission 
tomography (PET) offering the best opportunity for 
success with development and validation of suitable 
targeted radioligands. However, an ideal PET 
radiopharmaceutical is still missing.
11,12
 Like others, we
have used [
11
C]PBR28-PET (Figure 1) to image
neuroinflammation, targeting the 18-kDa translocator 
protein (TSPO) formerly named the peripheral 
benzodiazepine receptor (PBR).
13,14
 However, the
limitations
15,16
 of [
11
C]PBR28-PET such as low receptor
binding, high inter-subject variability in binding 
affinity, and nonspecific binding in the human brain, 
due to TSPO polymorphism, have motivated us to 
search for new molecular targets and PET radioligands. 
Increasing evidence suggests the P2X7 receptor as an 
interesting neuroinflammation-associated molecular 
target.
12,17
  Recently the synthesis and initial preclinical
evaluation of a P2X7 receptor radioligand [
11
C]A-
740003 (racemic compounds, Figure 1) have been 
reported, but it showed little uptake in brain in healthy 
male Wistar rats.
12
 We have instead initially focused on
GSK1482160 (a chiral compound, (S)-N-(2-chloro-3-
(trifluoromethyl)benzyl)-1-methyl-5-oxopyrrolidine-2-
carboxamide, 3). Originally developed by 
GlaxoSmithKline, GSK1482160 is a potent P2X7 
antagonist with excellent biological activity {PIC50 8.5 
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 (IC50 3 nM) for human P2X7, and PIC50 6.6 for rat 
P2X7}.
18-20
 This compound readily crosses the blood-
brain barrier (BBB), and has been evaluated as a 
therapeutic agent in a Phase 1 human study,
18-20
 making 
it an attractive candidate for possible translation to a 
PET diagnostic agent.  
 
Here we report the synthesis of [
11
C]GSK1482160 {(S)-
N-(2-chloro-3-(trifluoromethyl)benzyl)-1-[
11
C]methyl-
5-oxopyrrolidine-2-carboxamide, [
11
C]3} as a new 
candidate PET agent for imaging of P2X7 receptor.         
 
 
Figure 1. Chemical structures of [11C]PBR28, [11C]A-740003, 
[11C]GSK1482160, and [11C]GSK1482160 isomer 
 
The reference standard GSK1482160 was synthesized 
as shown in Scheme 1.
18,19
  L-Pyroglutamic acid or 
methyl L-pyroglutamate was reacted with methyl iodide 
(CH3I) and NaH in N,N-dimethylformamide (DMF) to 
convert into methyl (S)-1-methyl-5-oxopyrrolidine-2-
carboxylate (1) in 41-43% yield. Subsequently, 
compound 1 was de-esterified with NaOH to give (S)-1-
methyl-5-oxopyrrolidine-2-carboxylic acid (2) in 82% 
yield. Then compound 2 underwent a coupling reaction 
with 2-chloro-3-(trifluoromethyl)benzylamine, using 2-
ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) 
or 1-ethyl-3-(3-dimethylaminopropyl)carbodimide 
(EDAC) as catalyst, affording standard compound 3 in 
80% yield. 
 
 
Scheme 1. Synthesis of GSK1482160. Reagents, conditions and yields: 
(i) NaH, CH3I, DMF, 0 
C to RT, 5 h; 41-43%. (ii) 2 M NaOH, MeOH, 
reflux, 3 h; 82%. (iii) EEDQ, CH2Cl2, RT, 15 h; 80%. 
 
The radiolabeling precursors desmethyl-GSK1482160 
{(S)-N-(2-chloro-3-(trifluoromethyl)benzyl)-5-
oxopyrrolidine-2-carboxamide, 4} and Boc-protected 
desmethyl-GSK1482160 (tert-butyl (S)-(2-chloro-3-
(trifluoromethyl)benzyl)(5-oxopyrrolidine-2-
carbonyl)carbamate, 5), were synthesized as indicated 
in Scheme 2. The precursor desmethyl-GSK1482160 
was prepared from L-pyroglutamic acid and 2-chloro-3-
(trifluoromethyl)benzylamine, with EDAC and 1-
hydrobenzotrizole (HOBt) as catalysts,
21
 in 76% yield. 
The alternative radiochemistry precursor, Boc-protected 
desmethyl-GSK1482160, was prepared from desmethyl-
GSK1482160 with di-tert-butyl-dicarbonate {(Boc)2O} 
using base catalyst 4-dimethylaminopyridine (DMAP)
22
 
in acetonitrile in 44% yield.   
 
 
Scheme 2. Synthesis of desmethyl-GSK1482160 and Boc-protected 
desmethyl-GSK1482160. Reagents, conditions and yields: (i) EDAC, 
HOBt, DCM, RT, 15 h; 76%; (ii) (Boc)2O, Et3N, DMAP, CH3CN, RT, 15 
h; 44%. 
 
 
Scheme 3. Synthesis of GSK1482160 isomer. Reagents, conditions and 
yields:  (i) (Boc)2O, THF/H2O; 90%. (ii) NaH, CH3I, THF; 91%. (iii) 
THA, CH2Cl2, RT, 3 h; 91%. (iv) EEDQ, CH2Cl2, RT, 15 h; 78%. 
 
As a reference compound, the GSK1482160 isomer (S)-
N-(2-chloro-3-(trifluoromethyl)benzyl)-N-methyl-5-
oxopyrrolidine-2-carboxamide (9) was synthesized as 
outlined in Scheme 3. 2-Chloro-3-
(trifluoromethyl)benzylamine was reacted with (Boc)2O 
in THF and water (1:1) without catalyst to give Boc-
protected tert-butyl (2-chloro-3-
(trifluoromethyl)benzyl)carbamate (6) in 90% yield. 
Subsequently compound 6 was methylated with CH3I 
and NaH to afford tert-butyl (2-chloro-3-
(trifluoromethyl)benzyl)(methyl)carbamate (7) in 91% 
yield. Compound 7 was deprotected with trifluoroacetic 
acid (TFA) in CH2Cl2 to obtain 1-(2-chloro-3-
(trifluoromethyl)phenyl)-N-methylmethanamine (8) in 
91% yield. Then compound 8 was reacted with L-
pyroglutamic acid using similar synthetic method for 
standard compound 3 to produce GSK1482160 isomer 
in 78% yield. The 
1
H NMR spectra of compound 9 
showed it contained two epimers, since the methyl 
 group is located at the side chain amide. This steric 
factor does not apply to compound 5. Compound 9 was 
formed by the coupling reaction from two different 
reaction directions, which gave two epimers. The 
reaction mechanism for synthesis of compound 5 is the 
substitution reaction of amide; in addition, Boc is a 
bulky group, thus compound 5 was formed through a 
preferential reaction direction, and no epimers were 
seen in its 
1
H NMR spectra. 
 
Synthesis of [
11
C]GSK1482160 via the desmethyl-
GSK1482160 precursor is presented in Scheme 4. 
Precursor 4 underwent N-[
11
C]methylation
23-26 
using the 
reactive [
11
C]methylating agent [
11
C]methyl triflate 
([
11
C]CH3OTf)
27,28 
in acetonitrile at 80 °C under basic 
conditions (NaH) The product was isolated by semi-
preparative reverse-phase (RP) high performance liquid 
chromatography (HPLC) with a C-18 column,
 
and then 
concentrated by solid-phase extraction (SPE) with a 
disposable C-18 Plus Sep-Pak cartridge
29-31
 to produce 
the corresponding pure radiolabeled compound [
11
C]3 
in 40-50%  radiochemical yield, decay corrected to end 
of bombardment (EOB), based on [
11
C]CO2. This is a 1-
pot-1-step radiosynthesis.  
 
The desmethyl-GSK1482160 precursor contains both 
cyclic amide and side chain amide. Although the cyclic 
amide is more easily deprotonated and methylated than 
side chain amide, a minor by-product 
[
11
C]GSK1482160 isomer (S)-N-(2-chloro-3-
(trifluoromethyl)benzyl)-N-[
11
C]methyl-5-
oxopyrrolidine-2-carboxamide ([
11
C]9) was formed as 
well. The [
11
C]GSK1482160 and [
11
C]GSK1482160 
isomer were formed in a ~10:1 ratio from desmethyl-
GSK1482160. Different solid bases, such as NaOH, 
KOH, K2CO3, Cs2CO3 and NaH, were tested in the 
radiolabeling reaction, and NaH proved to be the best 
base for the N-[
11
C]methylation of cyclic amide.   
 
 
Scheme 4. Synthesis of [11C]GSK1482160 via precursor desmethyl-
GSK1482160. Reagents, conditions and yields: (i) [11C]CH3OTf, CH3CN, 
NaH, 80 C, 3 min; 40-50%. 
 
The synthesis of [
11
C]GSK1482160 via Boc-protected 
desmethyl-GSK1482160 is outlined in Scheme 5. The 
precursor 5 was labeled by [
11
C]CH3OTf
 
through N-
[
11
C]methylation
 
in dimethyl sulfoxide (DMSO) at 100 
°C under basic condition (K2CO3) to give a radiolabeled 
intermediate Boc-protected [
11
C]GSK1482160. This 
was followed by a quick deprotection reaction with 1 M 
HCl, without isolation, to provide the target tracer. The 
radiolabeling mixture was isolated by RP-HPLC 
combined with SPE to produce the corresponding pure 
radiolabeled compound [
11
C]3 in 30-40% decay-
corrected radiochemical yield. This is a 1-pot-2-step 
radiosynthesis.
22
 The best base for the radiolabeling 
reaction was freshly ground K2CO3 powder.   
 
 
Scheme 5. Synthesis of [11C]GSK1482160 via precursor BOC-protected 
desmethyl-GSK1482160. Reagents, conditions and yields: (i) 
[11C]CH3OTf, DMSO, K2CO3, 100 
C, 5 min; (ii) 1 M HCl, 100 C, 3 
min; 30-40%. 
 
Our approach employed more reactive [
11
C]CH3OTf, 
instead of commonly used [
11
C]methyl iodide 
([
11
C]CH3I),
32
 in [
11
C]methylation of the amide, and 
thus the radiochemical yield of [
11
C]3 was relatively 
high. It is important to note that the strong base NaH 
would help the N-[
11
C]methylation of unprotected 
amide precursor desmethyl-GSK1482160, and 
significantly increase the radiochemical yield of [
11
C]3. 
Therefore, the radiochemical yields for [
11
C]3 reported 
here are much higher than that the N-[
11
C]methylation 
of amide precursor with other base (KOH) reported 
previously.
25
 For the Boc-protected desmethyl-
GSK1482160 precursor, it was better to conduct the N-
[
11
C]methylation of amide under mildly basic 
conditions (K2CO3), since the Boc protecting group is 
not very stable under strongly basic conditions with 
high reaction temperature. Only a relatively small 
amount of the precursor (0.3-0.5 mg) was used for 
radiolabeling, instead of our more commonly used 
amount of the precursor (1.0-1.5 mg), which improved 
the chemical purity of the final tracer solution. 
Furthermore, addition of NaHCO3 solution to quench 
the radiolabeling reaction and to dilute the radiolabeling 
mixture prior to the injection onto the semi-preparative 
HPLC column for purification, gave better separation of 
[
11
C]3 from its unprotected or protected amide  
precursor (4 or 5).
29-31,33
  
 
The radiosynthesis was performed in a home-built 
automated multi-purpose [
11
C]-radiosynthesis 
module.
34-36
 This radiosynthesis module facilitated the 
overall design of the reaction, purification and 
reformulation capabilities in a fashion suitable for 
adaptation to preparation of human doses. In addition, 
the module is designed to allow in-process measurement 
of [
11
C]-tracer specific activity (SA, GBq/mol at EOB) 
using a radiation detector at the outlet of the HPLC-
 portion of the system.
26
 For the reported syntheses, 
product SA was in a range of 370-1110 GBq/mol at 
EOB.  
 
The factors that affect the EOB SA significantly to lead 
to such a wide range from 370 to 1110 GBq/mol are 
mainly from two parts: (1) carrier from the [
11
C]-target, 
and (2) carrier from the [
11
C]-radiosynthesis unit.
26
 We 
have optimized the [
11
C] gas irradiation target system 
and the [
11
C]-radiosynthesis unit to eliminate 
12
C 
carrier-added as much as possible and to reach the high 
end of the SA. To help produce high SA [
11
C]CO2, we 
usually do 2-3 10-minute target pre-burns, with the 
same beam current, prior to the actual production run. 
These pre-burn warm up the cyclotron target and 
eliminate significant amount of 
12
C carrier in the 
cyclotron’s [
11
C] gas target. We use an Eckert & Ziegler 
Modular Lab C-11 Methyl Iodide/Triflate module to 
produce [
11
C]CH3OTf, convenient gas phase 
bromination of [
11
C]methane, and production of 
[
11
C]CH3OTf. This ‘dry’ method, using Br2 to generate 
a [
11
C]CH3Br intermediate, differs from other ‘dry’ 
methods using I2 and ‘wet’ methods using LiAlH4 and 
HI, and seems to help minimize introduction of 
additional 
12
C carrier after [
11
C]CO2 production.
28
   
 
The 1-pot-1-step radiosynthesis via desmethyl-
GSK1482160 is a non-specific synthesis route, and 1-
pot-2-step radiosynthesis via Boc-protected desmethyl-
GSK1482160 is a specific synthesis route. The non-
specific route required lower reaction temperature, 
shorter reaction time, and shorter overall synthesis time. 
Consequently it gave higher radiochemical yield. In 
addition, it is easier to synthesize the precursor without 
Boc group than with Boc group. This route is somewhat 
simpler to implement as it avoids adding a deprotection 
step. Fortunately, this route proceeds with high 
selectivity (~10:1) for [
11
C]methylation at the N of the 
desired cyclic amide over the acyclic amide, and the 
desired product has been cleanly isolated after semi-
preparative HPLC purification of the radiolabeling 
reaction mixture. In comparison with these two 
radiosynthesis approaches, the non-specific route is 
identified as a more appropriate route for future 
applications.   
  
Chemical purity and radiochemical purity were 
determined by analytical HPLC.
37
 The chemical purity 
of the precursors and reference standards was >93%. 
The radiochemical purity of the target tracers was >99% 
determined by radio-HPLC through -ray (PIN diode) 
flow detector, and the chemical purity of the target 
tracers was >90% determined by reversed-phase HPLC 
through UV flow detector.   
 
The experimental details and characterization data for 
compounds 1-9 and for the tracer [
11
C]3 are given.
38 
 
 
In summary, synthetic routes with moderate to excellent 
yields have been developed to produce the precursors 
desmethyl-GSK1482160 and Boc-protected desmethyl-
GSK1482160; the reference standards GSK1482160 
and GSK1482160 isomer; and the target PET 
radiotracer [
11
C]GSK1482160. The radiosynthesis 
employed [
11
C]CH3OTf for N-[
11
C]methylation at the 
nitrogen position of the amide precursors, followed by 
product purification and isolation by a semi-preparative 
RP HPLC combined with solid-phase extraction. The 
desired [
11
C]GSK1482160 was obtained in high 
radiochemical yield, radiochemical purity and chemical 
purity, with a reasonably short overall synthesis time, 
and high specific activity. This will facilitate studies to 
evaluate [
11
C]GSK1482160 as a new PET 
radiopharmaceutical for targeting the P2X7 receptor in 
animals and humans.  
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(b) Methyl (S)-1-methyl-5-oxopyrrolidine-2-
carboxylate (1): Method A (from L-pyroglutamic 
acid). To a stirred suspension of sodium hydride (60% 
dispersion in mineral oil, 2.1 g, 52 mmol) in DMF (60 
mL) at 0 °C under nitrogen, L-pyroglutamic acid (2.58 
g, 20 mmol) was added during 15 min. The mixture 
was stirred at room temperature (RT) for 1 h. While 
ice cooling and stirring, iodomethane (7.76 g, 55 
mmol) was added and the reaction mixture was 
allowed to warm to RT overnight. The solvent was 
evaporated under reduced pressure, and water was 
added. After pH was adjust to 5 with adding acetic 
acid, the aqueous layer was extracted with CH2Cl2 
(100 mL × 3). The organic layer was concentrated, 
and the residue was purified by column 
chromatography on silica gel with eluent (30:70 
EtOAc/hexanes) to give colorless oily product 1 (1.35 
g, 43%). Rf = 0.68 (1:19 MeOH/CH2Cl2). 
1
H NMR 
(CDCl3):  2.07-2.09 (m, 1H, CH), 2.33-2.40 (m, 2H, 
CH2), 2.47-2.49 (m, 1H, CH), 2.85 (s, 3H, NCH3), 
3.78 (s, 3H, OCH3), 4.12 (dd, J = 3.0, 8.0 Hz, 1H, 
CH). MS (ESI): 158 ([M+H]
+
, 100%). Method B 
(from methyl L-pyroglutamate). Methyl L-
pyroglutamate (1.43 g, 10 mmol was dissolved in 
DMF (25 mL) and cooled to 0 °C. Sodium hydride 
(60% suspension in mineral oil, 0.6 g, 15 mmol) was 
added to the reaction mixture and stirred for 1 h. Then 
methyl iodide (2.11 g, 15 mmol) was added slowly, 
the mixture was allowed to warm to RT and stirred for 
another 1 h. The solvent was evaporated in vacuo, and 
water was added, subsequently acetic acid was added 
to adjust pH to 5, the aqueous layer was then extracted 
with CH2Cl2 (60 mL × 3). The organic layer was 
concentrated, and the residue was purified by column 
chromatography on silica gel with eluent (30:70 
EtOAc/hexanes) to yield colorless oily product 1 (0.64 
g, 41%). Analytical data was identical with Method A.  
(c) (S)-1-Methyl-5-oxopyrrolidine-2-carboxylic acid 
(2): Compound 1 (0.47 g, 3.0 mmol) was dissolved in 
methanol (20 mL), and to this solution was added 2 M 
NaOH (3 mL, 6.0 mmol). The mixture was refluxed 
for 3 h, then cooled and evaporated to leave a minimal 
amount of water. This mixture was acidified to pH 2 
using 1 M aqueous HCl. The aqueous was extracted 
with CH2Cl2 (100 mL × 3), and organic layer was 
washed with water, dried over MgSO4. The solvent 
was evaporated to afford white solid compound 2 
(0.35 g, 82%). Rf = 0.11 (1:5 MeOH/CH2Cl2), mp 
148–150 °C. 1H NMR (DMSO-d6):  1.92-1.94 (m, 
1H, CH), 2.19-2.30 (m, 3H, CH2 and CH), 2.69 (s, 3H, 
NCH3), 4.11 (dd, J = 3.8, 8.8 Hz, 1H, CH), 12.97 (s, 
1H, COOH). MS (ESI): 309 ([2M+Na]
+
, 20%), 287 
([2M+H]
+
, 100%), 144 ([M+H]
+
, 60%).    
(d) (S)-N-(2-Chloro-3-(trifluoromethyl)benzyl)-1-
methyl-5-oxopyrrolidine-2-carboxamide 
(GSK1482160, 3): Compound 2 (286 mg, 2.0 mmol) 
was suspended in CH2Cl2 (60 mL), and EEDQ (543 
mg, 2.2 mmol) was added. The mixture was stirred at 
RT for 10 min. A solution of 2-chloro-3-
(trifluoromethyl)benzylamine (440 mg, 2.1 mmol) in 
CH2Cl2 (20 mL) was then added dropwise to the 
mixture. The mixture was then stirred at RT overnight. 
The mixture was washed with saturated aqueous 
NaHCO3 (40 mL), 2 N aqueous HCl (40 mL × 2), and 
water. The organic solution was dried over Na2SO4, 
filtered and concentrated in vacuo. The resulting crude 
product was then purified by column chromatography 
on silica gel with eluent (2:98 MeOH/CH2Cl2) to 
obtain white solid product 3 (534 mg, 80%). Rf = 0.53 
(1:12 MeOH/CH2Cl2), mp 166-168 °C. 
1
H NMR 
(acetone-d6):  1.96-2.03 (m, 1H, CH), 2.18-2.21 (m, 
1H, CH), 2.28-2.36 (m, 1H, CH2), 2.77 (s, 3H, NCH3), 
4.17 (dd, J = 3.5, 8.5 Hz, 1H, CH), 4.63 (d, J = 6.0 Hz, 
2H, CH2), 7.55 (t, J = 8.0 Hz, 1H, Ph-H), 7.75 (t, J = 
8.0 Hz, 2H, Ph-H), 8.05 (br s, 1H, NH). MS (ESI): 
335 ([M+H]
+
, 100%); MS (ESI): 333 ([M-H]
-
, 50%).  
(e) (S)-N-(2-Chloro-3-(trifluoromethyl)benzyl)-5-
oxopyrrolidine-2-carboxamide (desmethyl-
GSK1482160, 4):  L-Pyroglutamic acid (516 mg, 4.0 
mmol) and 2-chloro-3-(trifluoromethyl)benzylamine 
(838 mg, 4.0 mmol) were mixed with EDAC

HCl (959 
mg, 5.0 mmol) and HOBt (676 mg, 5.0 mmol) in dry 
CH2Cl2 (100 mL). The reaction mixture was stirred at 
RT for overnight. Then the resultant mixture was 
washed with 2 N HCl (50 mL × 3) and saturated 
aqueous NaHCO3 (40 mL). The organic layer was 
dried over Na2SO4 and concentrated. The residue was 
purified by column chromatography on silica gel with 
eluent (2:98 MeOH/CH2Cl2) to afford white solid 
product 4 (975 mg, 76%). Rf = 0.47 (1:12 
MeOH/CH2Cl2), mp 173-175 °C. 
1
H NMR (acetone-
d6):  2.10-2.19  (m, 2H, CH2), 2.23-2.28 (m, 1H, 
CH), 2.44-2.49 (m, 1H, CH), 4.23-4.25 (m, 1H, CH), 
4.55-4.65 (m, 2H, CH2), 7.07 (br s, 1H, NH), 7.51 (t, J 
= 8.0 Hz, 1H, Ph-H), 7.73 (t, J = 7.5 Hz, 2H, Ph-H), 
8.00 (br s, 1H, NH). 
13
C NMR (acetone-d6):  26.65, 
29.84, 41.36, 57.34, 123.07 (q, JC-F = 270.8 Hz, CF3), 
127.28 (q, JC-F = 5.5 Hz), 128.08, 128.79 (q, JC-F = 
30.6 Hz), 131.34, 133.84, 140.21, 173.80, 178.43. MS 
(ESI): 321 ([M+H]
+
, 100%).  HRMS (ESI): calcd for 
C13H12N2O2ClF3Na ([M+Na]
+
) 343.0437, found 
343.0432.    
(f) tert-Butyl (S)-(2-chloro-3-
(trifluoromethyl)benzyl)(5-oxopyrrolidine-2-
carbonyl)carbamate (Boc-protected desmethyl-
GSK1482160, 5): Compound 4 (300 mg, 0.93 mmol) 
and (Boc)2O (430 mg, 1.97 mmol) were mixed with 
DMAP (115 mg, 0.93 mmol) and Et3N (142 mg, 1.4 
mmol) in acetonitrile (50 mL).  The reaction mixture 
was stirred at RT for 24 h. The resulting mixture was 
 concentrated, and the residue was purified by column 
chromatography on silica gel with eluent (2:98 
MeOH/CH2Cl2) to give white solid product 5 (173 mg, 
44%). Rf = 0.46 (1:19 MeOH/CH2Cl2), mp 145-147 
°C. 
1
H NMR (CDCl3):  1.39 (s, 9H, 3 × CH3), 2.14-
2.20 (m, 1H, CH), 2.22-2.29 (m, 1H, CH), 2.43-2.49 
(m, 1H, CH), 2.70-2.78 (m, 1H, CH), 4.53 (dd, J = 
2.8, 7.8 Hz, 1H, CH), 4.57-4.67 (m, 2H, NCH2), 6.88 
(s, 1H, Ph-H), 7.34 (t, J = 7.5 Hz, 1H, Ph-H), 7.63 (d, 
J = 7.5 Hz, 2H, Ph-H). 
13
C NMR (CDCl3):  22.08, 
27.82, 31.66, 41.55, 60.17, 83.99, 121.74 (q, JC-F = 
271.6 Hz, CF3), 126.83, 126.90 (q, JC-F = 5.3 Hz), 
128.93 (q, JC-F = 30.9 Hz), 131.51, 133.53, 137.90, 
150.03, 171.01, 173.89. MS (ESI): 419 ([M-H]
-
, 1%). 
HRMS (ESI): calcd for C18H20N2O4ClF3Na ([M+Na]
+
) 
443.0961, found 443.0972.  
(g) tert-Butyl (2-chloro-3-
(trifluoromethyl)benzyl)carbamate (6): 2-Chloro-3-
(trifluoromethyl)benzylamine (210 mg, 1.0 mmol) was 
dissolved in THF-water (1:1) and then (Boc)2O (229 
mg, 1.05 mmol) was added to the solution. The 
reaction mixture was stirred at RT for overnight. Then 
the mixture was concentrated in vacuo, and cooled 
down. The resulting precipitate was filtered, washed 
with water, and dried, affording white solid product 6 
(278 mg, 90%). Rf = 0.60 (1:5 EtOAc/hexanes), mp 
98-100 °C. 
1
H NMR (CDCl3):  1.45 (s, 9H, 3 × CH3), 
4.45 (d, J = 6.0 Hz, 2H, CH2), 5.05 (s, 1H, NH), 7.35 
(t, J = 7.5 Hz, 1H, Ph-H), 7.59 (d, J = 7.5 Hz, 1H, Ph-
H), 7.62 (d, J = 7.5 Hz, 1H, Ph-H). MS (ESI): 308 
([M-H]
-
, 1%).  
(h) tert-Butyl (2-chloro-3-
(trifluoromethyl)benzyl)(methyl)carbamate (7): 
Sodium hydride (60% dispersion in mineral oil, 152 
mg, 3.8 mmol) was added dropwise into a solution of 
compound 6 (588 mg, 1.9 mmol) in THF (60 mL) at 0 
°C. After 30 min methyl iodide (809 mg, 5.7 mmol) 
was added. The mixture was reacted at RT for 3 h. 
The reaction mixture was concentrated in vacuo, and 
thereto was added water in an ice bath. Then it was 
extracted with ethyl acetate, and washed with brine. 
The organic layer was dried over Na2SO4 and 
concentrated. The residue was purified by column 
chromatography on silica gel with eluent (10:90 
EtOAc/hexanes) to give colorless oily product 7 (559 
mg, 91%). Rf = 0.63 (1:5 EtOAc/hexanes). 
1
H NMR 
(CDCl3):  1.41 and 1.50 (s, 9H, 3 × CH3), 2.89 and 
2.92 (s, 3H, NCH3), 4.57 and 4.62 (s, 2H, CH2), 7.36 
(d, J = 7.0 Hz, 2H, Ph-H), 7.62 (s, 1H, Ph-H).  
(i) 1-(2-Chloro-3-(trifluoromethyl)phenyl)-N-
methylmethanamine (8): Compound 7 (485 mg, 1.5 
mmol) with TFA (1.0 mL) was dissolved in CH2Cl2 
(10 mL) at RT. After stirring for 3 h, the solvent was 
removed, and the residue was dissolved in ethyl 
acetate, which was washed with aqueous Na2CO3 
followed by brine. The organic layer was dried over 
Na2SO4 and concentrated. The residue was purified by 
column chromatography on silica gel with eluent (2:98 
MeOH/CH2Cl2) to afford yellowish oily product 8 
(305 mg, 91%). Rf = 0.52 (1:9 MeOH/CH2Cl2). 
1
H 
NMR (CDCl3):  2.48 (s, 3H, NCH3), 3.91 (s, 2H, 
CH2), 7.35 (t, J = 8.0 Hz, 1H, Ph-H), 7.6 (d, J = 8.0 
Hz, 2H, Ph-H). MS (ESI): 224 ([M+H]
+
, 100%). 
(j) (S)-N-(2-Chloro-3-(trifluoromethyl)benzyl)-N-
methyl-5-oxopyrrolidine-2-carboxamide 
(GSK1482160 isomer, 9):  This compound was 
prepared from compound 8 and L-pyroglutamic acid 
using similar procedure for the preparation of 
compound 3, affording white solid product 9 in 78% 
yield. Rf = 0.64 (1:9 MeOH/CH2Cl2). 
1
H NMR 
(acetone-d6):  2.09-2.28 (m, 3H, CH2 and CH), 2.24-
2.54 (m, 1H, CH), 2.96 and 3.19 (s, 3H, NCH3), 4.57-
4.86 (m, 3H, CH2 and CH), 7.00 and 7.07 (s 1H, Ph-
H), 7.51-7.63 (m, 1H, Ph-H), 7.74-7.82 (m, 1H, Ph-
H). MS (ESI): 335 ([M+H]
+
, 100%); MS (ESI): 333 
([M-H]
-
, 6%).  
(k) (S)-N-(2-Chloro-3-(trifluoromethyl)benzyl)-1-
[
11
C]methyl-5-oxopyrrolidine-2-carboxamide, 
([
11
C]GSK1482160, [
11
C]3): Method A (from 
desmethyl-GSK1482160, 4). [
11
C]CO2 was produced 
by the 
14
N(p,)11C nuclear reaction in the small 
volume (9.5 cm
3
) aluminum gas target provided with 
the Siemens RDS-111 Eclipse cyclotron. The target 
gas consisted of 1% oxygen in nitrogen purchased as a 
specialty gas from Praxair, Indianapolis, IN. Typical 
irradiations used for the development were 55 A 
beam current and 30 min on target.  The production 
run produced approximately 45.5 GBq of [
11
C]CO2 at 
EOB. In a small reaction vial (5 mL), the precursor 4 
(0.3-0.5 mg) was dissolved in CH3CN (500 L).  To 
this solution was added NaH (1 mg). No carrier-added 
(high specific activity) [
11
C]CH3OTf that was 
produced by the gas-phase production method
28
 from 
[
11
C]CO2 through [
11
C]CH4 and [
11
C]CH3Br with 
silver triflate (AgOTf) column was passed into the 
reaction vial at RT, until radioactivity reached a 
maximum (~2 min), and then the reaction vial was 
isolated and heated at 80 

C for 3 min. The contents of 
the reaction vial were diluted with NaHCO3 solution 
(0.1 M, 1 mL), and injected onto the semi-preparative 
RP HPLC column with 3 mL injection loop for 
purification. The product fraction was collected in a 
recovery vial containing 30 mL water. The diluted 
tracer solution was then passed through a C-18 Sep-
Pak Plus cartridge, and washed with water (5 mL × 4).  
The cartridge was eluted with EtOH (1 mL  2), 
followed by 10 mL saline, to release [
11
C]3.  The 
eluted product was then sterile-filtered through a 
sterile vented Millex-FG 0.2 m filter, and collected 
into a sterile vial. Total radioactivity (4.6-8.2 GBq) 
was assayed and total volume (10-11 mL) was noted 
for tracer dose dispensing. The overall synthesis, 
purification and formulation time was 30-40 min from 
EOB.  Retention times in the analytical HPLC system 
were: tR 4 = 2.84 min, tR 3 = 4.39 min, , tR 9 = 3.56 
min, tR [
11
C]3 = 4.41 min, and tR [
11
C]9 = 3.60 min. 
Retention times in the semi-preparative HPLC system 
 were: tR 4 = 3.63 min, tR 3 = 7.13 min, , tR 9 = 5.68 
min, tR [
11
C]3 = 7.21 min, and tR [
11
C]9 = 5.79 min. 
The radiochemical yield of [
11
C]3 was 40-50% decay 
corrected to EOB, based on [
11
C]CO2. Method B 
(from Boc-protected desmethyl-GSK1482160, 5). The 
precursor 5 (0.3-0.5 mg) was dissolved in DMSO (500 
L) in a 5-mL V-vial. To this solution was added dry 
K2CO3 powder (1 mg). [
11
C]CH3OTf was passed into 
the reaction vial at RT until radioactivity reached a 
maximum (~2 min), and then the reaction vial was 
isolated and heated at 100 °C for 5 min to form a 
radiolabeled intermediate Boc-protected 
[
11
C]GSK1482160. Then, a solution of 1 N HCl (500 
L) was introduced to the reaction vial. The reaction 
mixture was sealed and heated at 100 °C for 3 min. 
The contents of the reaction vial were diluted with 
NaHCO3 (0.1 M, 1 mL), and injected onto the semi-
preparative HPLC column with 3 mL injection loop 
for purification. The purification and formulation 
procedures were same with Method A. The overall 
synthesis, purification and formulation time was ~40 
min from EOB. Retention times in the analytical 
HPLC system were: tR 5 = 5.27 min, tR 3 = 4.39 min, 
and tR [
11
C]3 = 4.41 min. Retention times in the semi-
preparative HPLC system were: tR 5 = 8.92 min, tR 3 = 
7.13 min, and tR [
11
C]3 = 7.21 min. The decay 
corrected radiochemical yields were 30-40%. 
